- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.04. | Obsidian, Galera Therapeutics Merger Comes With $350M Infusion for Cancer Drug Trials | 2 | MedCity News | ||
| 15.04. | Obsidian, Galera Therapeutics to advance cell therapy following reverse merger | 4 | BioPharma Dive | ||
| 15.04. | Obsidian Therapeutics To Merge With Galera Therapeutics In Reverse Merger | - | RTTNews | ||
| 15.04. | Obsidian Therapeutics to go public via Galera Therapeutics merger | 2 | Investing.com | ||
| 15.04. | Fusion mit Galera Therapeutics: Obsidian Therapeutics strebt Börsengang an | 3 | Investing.com Deutsch | ||
| 15.04. | RTW Biotech Opp. - Obsidian Therapeutics reverse merger with Galera Therapeutics | - | RNS | ||
| 14.04. | Galera Therapeutics und Obsidian kündigen Fusion und 350-Millionen-Dollar-Finanzierung an | 2 | Investing.com Deutsch | ||
| GALERA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 14.04. | Galera Therapeutics to merge with Obsidian in $350M deal | 2 | Investing.com | ||
| 14.04. | Cell therapy biotech Obsidian leverages Galera Therapeutics reverse merger to go public | 1 | FierceBiotech | ||
| 14.04. | Fusion von Galera Therapeutics und Obsidian Therapeutics: Neues Biotech-Unternehmen sichert sich 350 Millionen US-Dollar | 1 | Investing.com Deutsch | ||
| 14.04. | Obsidian Therapeutics, Inc. and Galera Therapeutics, Inc. Announce Merger Agreement and $350 Million Concurrent Private Placement | 154 | Business Wire | • Combined company to operate as Obsidian Therapeutics, Inc. and to advance Obsidian's pipeline of novel engineered TIL cell therapies for the treatment of patients with solid tumors.
• Obsidian's... ► Artikel lesen | |
| 14.04. | Galera Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.04. | Galera Therapeutics bündelt jährliche Hauptversammlungen für 2025 und 2026 und setzt Termin für Mai fest | 4 | Investing.com Deutsch | ||
| 03.04. | Galera Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 19.03. | Galera Therapeutics, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 12.02. | Galera Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.11.25 | Galera Therapeutics, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 22.10.25 | Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million | 1.025 | GlobeNewswire (Europe) | Galera has entered into an Asset Purchase Agreement with Toronto-based Biossil for Galera's dismutase mimetics portfolio, including all avasopasem and rucosopasem formulations and indications. The... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 43,400 | +4,25 % | CRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy? | ||
| NOVOCURE | 10,630 | -0,23 % | Novocure to Report First Quarter 2026 Financial Results | Novocure (NASDAQ: NVCR) will report financial results for the first quarter 2026 on April 30, 2026, before the U.S. financial markets open.
Novocure management will host a conference call and webcast... ► Artikel lesen | |
| SPERO THERAPEUTICS | 2,414 | +2,99 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update | Spero announced the resubmission of tebipenem HBr New Drug Application (NDA) to the FDA for complicated urinary tract infections (cUTI), including pyelonephritis in December 2025In February, Spero's... ► Artikel lesen | |
| PRECISION BIOSCIENCES | 6,400 | +6,31 % | Precision BioSciences, Inc.: Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026 | Late-breaking poster presentation to highlight new biopsy data demonstrating elimination and inactivation of cccDNA from the ongoing Phase 1 ELIMINATE-B trial in chronic hepatitis B
Precision... ► Artikel lesen | |
| BOLT BIOTHERAPEUTICS | 5,820 | -100,00 % | Bolt BioTherapeutics GAAP EPS of -$3.84 beats by $1.57, revenue of $2.5M beats by $1.64M | ||
| ARCELLX | 115,03 | -0,01 % | Arcellx, Inc. - 10-K/A, Annual Report | ||
| SUMMIT THERAPEUTICS | 22,080 | -0,81 % | Stifel reiterates Summit Therapeutics stock rating on trial data | ||
| QIAGEN | 32,580 | +0,12 % | Aktien New York Ausblick: Moderate Gewinne - Lage in Nahost sorgt für Vorsicht | NEW YORK (dpa-AFX) - Am US-Aktienmarkt werden am Dienstag zum Handelsstart moderate Gewinne erwartet. Angesichts der unsicheren Lage in Nahost dominiert - wie bereits zum Wochenstart - die Vorsicht.... ► Artikel lesen | |
| ERASCA | 21,490 | -4,40 % | Erasca, Inc. - 8-K, Current Report | ||
| ADMA BIOLOGICS | 11,260 | +1,67 % | ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today? | ||
| BEAM THERAPEUTICS | 27,105 | -10,13 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| RELAY THERAPEUTICS | 15,130 | +0,33 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026 | 400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-2025 11.1-month median PFS in heavily pre-treated patients with PI3Ka-mutated, HR+/HER2- metastatic breast... ► Artikel lesen | |
| TANGO THERAPEUTICS | 25,760 | -0,43 % | Stifel reiterates Tango Therapeutics stock rating on combo potential | ||
| ENVERIC BIOSCIENCES | 5,020 | +24,57 % | What's Going On With Enveric Biosciences Stock On Friday? | ||
| EVOTEC | 5,350 | -0,93 % | Insiderverkäufe, Kaufempfehlungen und KI-Fantasie: BioNTech, Evotec, Vidac Pharma Aktie. | Insiderverkäufe bei Vidac Pharma. Dies ist jedoch kein Alarmsignal, sondern bietet eher eine Einstiegschance. Das Unternehmen arbeitet an einer revolutionären Krebstherapie. In 2026 sollen wichtige... ► Artikel lesen |
GALERA THERAPEUTICS INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GALERA THERAPEUTICS INC finden Sie auf Wallstreet Online.